Stereotaxis, Inc.’ STOP-VT Prospective Multicenter Study Results Featured at Europe’s Largest Medical Meeting, European Society of Cardiology

ST. LOUIS--(BUSINESS WIRE)--Stereotaxis, Inc. (NASDAQ: STXS) announced today that the results of the Study to Obliterate Persistent Ventricular Tachycardia (STOP-VT) was presented at the European Society of Cardiology (ESC) 2011 Congress held in Paris, France on Sunday, August 28.

MORE ON THIS TOPIC